SCHEMBL25707635

SCHEMBL25707635

CCCCCCC(CCCCC)CCCN1CC2(CCN(C(=O)C(CCCC)CCCC)CC2)C1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
TSHR P16473 2/20 0.37
USP2 O75604 1/20 0.37
CA2 P00918 1/20 0.36
S1PR1 P21453 2/20 0.35
S1PR3 Q99500 2/20 0.35
S1PR5 Q9H228 2/20 0.35
S1PR4 O95977 1/20 0.35
ALDH1A1 P00352 1/20 0.34
CHRM3 P20309 1/20 0.33
EPHX2 P34913 1/20 0.32
BCHE P06276 5/20 0.32
CYP2D6 P10635 1/20 0.32
OPRL1 P41146 1/20 0.32
CCKBR P32239 1/20 0.31
GRIK1 P39086 1/20 0.31
GRIK2 Q13002 1/20 0.31
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26405356 0.95 USP2 (0.38) LMNATSHRUSP2CA2S1PR1
SCHEMBL25923944 0.95 TSHR (0.35) LMNATSHRUSP2CA2S1PR1
SCHEMBL25927357 0.95 TSHR (0.37) LMNATSHRUSP2CA2S1PR1
SCHEMBL25122691 0.95 TSHR (0.37) LMNATSHRUSP2CA2S1PR1
SCHEMBL23945776 0.93 LMNA (0.37) LMNATSHRUSP2CA2S1PR1
SCHEMBL25884460 0.93 LMNA (0.37) LMNATSHRUSP2CA2S1PR1
SCHEMBL25123610 0.92 ACE2 (0.38) LMNATSHRUSP2CA2S1PR1
SCHEMBL25110655 0.90 CYP2D6 (0.36) LMNATSHRUSP2CA2S1PR1
SCHEMBL23696049 0.90 S1PR1 (0.40) USP2CA2S1PR1S1PR3S1PR5
SCHEMBL25707293 0.89 TSHR (0.39) LMNATSHRUSP2CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190940-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190940-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 LMNA 1656/4885TSHR 3319/4885USP2 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.